Stoke Therapeutics, Inc.
STOK
$31.16
-$1.34-4.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -50.00M | -57.93M | -38.35M | -23.48M | 112.88M |
| Total Depreciation and Amortization | 439.00K | 405.00K | 442.00K | 446.00K | 477.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.00M | 10.10M | 8.66M | 8.74M | 6.86M |
| Change in Net Operating Assets | -20.01M | 16.98M | -1.12M | -11.12M | 11.61M |
| Cash from Operations | -60.58M | -30.45M | -30.37M | -25.42M | 131.83M |
| Capital Expenditure | -353.00K | -232.00K | -132.00K | -154.00K | -152.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 51.05M | -60.83M | 9.23M | -148.32M | 13.78M |
| Cash from Investing | 50.69M | -61.06M | 9.09M | -148.48M | 13.63M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 84.33M | 92.34M | 3.12M | 554.00K | 1.37M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 84.33M | 92.34M | 3.12M | 554.00K | 1.37M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 74.44M | 826.00K | -18.15M | -173.35M | 146.83M |